A crossover study of risperidone in children, adolescents and adults with mental retardation.
Risperidone has shown safety and efficacy for aggressive and destructive behaviors in short-term studies. This longer-duration study includes a broad sample. Forty subjects, aged 8-56 years (mean=22), all with mental retardation and 36 with autism spectrum disorders participated in this 22-week crossover study, with 24 weeks of open maintenance thereafter. Of 40 subjects, 23 (57.5%) responded fully (50% decrease in Aberrant Behavior Checklist-Community Irritability subscale score), while 35 subjects (87.5%) showed a 25% decrease. Gender, mood disorder, and antiseizure medications did not alter response. Increased appetite and weight gain were common. Low dose risperidone was effective for aggressive behavior in persons with MR. More long-term studies are needed, incorporating weight control interventions.
Hellings
Jessica A
JA
Department of Psychiatry, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, USA. jhelling@kumc.edu
Zarcone
Jennifer R
JR
Reese
R Matthew
RM
Valdovinos
Maria G
MG
Marquis
Janet G
JG
Fleming
Kandace K
KK
Schroeder
Stephen R
SR
D000293:Adolescent; D000328:Adult; D000374:Aggression / Q000523:psychology*; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001321:Autistic Disorder / Q000453:epidemiology* / Q000523:psychology*; D002648:Child; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008607:Intellectual Disability / Q000453:epidemiology / Q000523:psychology*; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy* / Q000453:epidemiology*; D008875:Middle Aged; D018967:Risperidone / Q000009:adverse effects* / Q000627:therapeutic use; D015430:Weight Gain / Q000187:drug effects*
D014150:Antipsychotic Agents; D018967:Risperidone